203 related articles for article (PubMed ID: 29053481)
1. Programmed Death Ligand 1 Expression Among 700 Consecutive Endometrial Cancers: Strong Association With Mismatch Repair Protein Deficiency.
Li Z; Joehlin-Price AS; Rhoades J; Ayoola-Adeola M; Miller K; Parwani AV; Backes FJ; Felix AS; Suarez AA
Int J Gynecol Cancer; 2018 Jan; 28(1):59-68. PubMed ID: 29053481
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
3. β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas.
Rowe M; Krishnan R; Mills A; Ring K
Int J Gynecol Cancer; 2020 Jul; 30(7):993-999. PubMed ID: 32376735
[TBL] [Abstract][Full Text] [Related]
4. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer.
Zong L; Sun Z; Mo S; Lu Z; Yu S; Xiang Y; Chen J
Gynecol Oncol; 2021 Sep; 162(3):631-637. PubMed ID: 34272092
[TBL] [Abstract][Full Text] [Related]
6. Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Willis BC; Sloan EA; Atkins KA; Stoler MH; Mills AM
Mod Pathol; 2017 Nov; 30(11):1622-1632. PubMed ID: 28752845
[TBL] [Abstract][Full Text] [Related]
7. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
Hacking S; Jin C; Komforti M; Liang S; Nasim M
Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
[TBL] [Abstract][Full Text] [Related]
8. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
Kim J; Kim S; Lee HS; Yang W; Cho H; Chay DB; Cho SJ; Hong S; Kim JH
Gynecol Oncol; 2018 May; 149(2):381-387. PubMed ID: 29572029
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic characteristics, tumor infiltrating lymphocytes and programed cell death ligand-1 expression in 162 endometrial carcinomas with deficient mismatch repair function.
Chavez JA; Wei L; Suarez AA; Parwani AV; Li Z
Int J Gynecol Cancer; 2019 Jan; 29(1):113-118. PubMed ID: 30640692
[TBL] [Abstract][Full Text] [Related]
10. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2,3-dioxygenase in endometrial cancer: a targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas.
Mills A; Zadeh S; Sloan E; Chinn Z; Modesitt SC; Ring KL
Mod Pathol; 2018 Aug; 31(8):1282-1290. PubMed ID: 29559741
[TBL] [Abstract][Full Text] [Related]
12. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression.
Lin SY; Hang JF; Lin YY; Lai CR; Ho HL; Chou TY
Int J Gynecol Pathol; 2021 Mar; 40(2):148-155. PubMed ID: 32897958
[TBL] [Abstract][Full Text] [Related]
13. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
Kir G; Soylemez T; Olgun ZC; Aydin A; McCluggage WG
Virchows Arch; 2020 Dec; 477(6):845-856. PubMed ID: 32594230
[TBL] [Abstract][Full Text] [Related]
14. The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma.
Mills AM; Dill EA; Moskaluk CA; Dziegielewski J; Bullock TN; Dillon PM
Am J Surg Pathol; 2018 Feb; 42(2):183-191. PubMed ID: 28914717
[TBL] [Abstract][Full Text] [Related]
15. Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study.
Pina A; Wolber R; McAlpine JN; Gilks B; Kwon JS
Int J Gynecol Cancer; 2018 Oct; 28(8):1624-1630. PubMed ID: 30095707
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer.
Wang Y; Lin J; Cui J; Han T; Jiao F; Meng Z; Wang L
Oncotarget; 2017 Feb; 8(6):9354-9365. PubMed ID: 28030840
[TBL] [Abstract][Full Text] [Related]
18. Expression of epigenetic pathway related genes in association with PD-L1, ER/PgR and MLH1 in endometrial carcinoma.
Saglam O; Cao B; Wang X; Toruner GA; Conejo-Garcia JR
PLoS One; 2022; 17(2):e0264014. PubMed ID: 35226658
[TBL] [Abstract][Full Text] [Related]
19. Expression of Immunomodulatory Molecules PD-1, PD-L1, and PD-L2, and their Relationship With Clinicopathologic Characteristics in Endometrial Cancer.
Sungu N; Yildirim M; Desdicioglu R; Başaran Aydoğdu Ö; Kiliçarslan A; Tatli Doğan H; Kiliç Yazgan A; Akyol M; Erdoğan F
Int J Gynecol Pathol; 2019 Sep; 38(5):404-413. PubMed ID: 30134343
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer.
Kucukgoz Gulec U; Kilic Bagir E; Paydas S; Guzel AB; Gumurdulu D; Vardar MA
Arch Gynecol Obstet; 2019 Aug; 300(2):377-382. PubMed ID: 31076855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
